FlandersBio on Twitter

Follow us on Twitter

Archive for November 2012 - News

Archive for November 2012 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Ghent University and MDxHealth Collaborate to Establish a Center in Pharmaco (Epi)genomics

30.11.2012

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced that it has joined forces with the Ghent University to establish NXTGNT, a new Center in Pharmaco (Epi)genomics. read more

ThromboGenics Lands Licensing Deal of the Year at SCRIP Awards 2012

30.11.2012

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that it won the Licensing Deal of the Year Award at the Scrip Awards 2012 event held in London last night. The Company received the global industry recognition for its partnership agreement with Alcon (Novartis) to commercialize JETREA® (ocriplasmin) outside the U.S. JETREA® is the first pharmacological treatment for vitreomacular adhesion (VMA), a progressive sight-threatening disease. JETREA® was recently approved by the U.S. Food and Drugs Administration for the treatment of symptomatic Vitreomacular Adhesion (VMA). The JETREA® European Marketing Authorisation Application is currently under review by the European Medicines Agency. A decision on European approval is expected in the first half of 2013. read more

ThromboGenics’ Shares to Join the STOXX600 Index

30.11.2012

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that its shares will be promoted to the STOXX Europe 600 Index from 24th December 2012. read more

MDxHealth announces its delisting from Euronext Amsterdam

29.11.2012

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, currently listed on Euronext Brussels and Euronext Amsterdam, announced today that it will de-list from Euronext Amsterdam effective as of 31 December 2012. The company considers that the Euronext is one trading platform and that a double listing is not justified anymore in the view of the increased costs which it implies. The company will remain listed on Euronext Brussels and does not expect that the de-listing from Euronext Amsterdam will have an impact on the liquidity for investors and potential investors. read more

Q-Biologicals signs a Service Framework Agreement with Virbac

29.11.2012

Q-Biologicals, a young biotech company providing services to third parties in the field of process development and manufacturing of biologicals, announces that it has signed a service framework agreement with Virbac SA, the French veterinary company. Q-Biologicals will collaborate with Virbac in the development of technologies and production processes suitable for Virbac biological projects in Animal Health. With this agreement, Virbac prolongs the existing relationship with Q-Biologicals and will be able to use Q-Biologicals’ expertise in the production of recombinant proteins, viruses and microbial live cells. read more

Apitope Completes Recruitment into its Clinical Trial of ATX-MS-1467 in Multiple Sclerosis

28.11.2012

Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS). Receipt of the first dose of study treatment by the last patient to be recruited prompted an undisclosed clinical milestone payment from Merck Serono, a division of Merck, Germany, with whom Apitope is developing ATX-MS-1467. read more

JETREA® Selected for Single Technology Appraisal (STA) by the UK’s National Institute for Health and Clinical Excellence (NICE)

28.11.2012

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that JETREA® (ocriplasmin) has been selected to receive a Single Technology Appraisal (STA) from the UK’s National Institute for Health and Clinical Excellence (NICE). The outcome of the STA, in the form of NICE guidance, is expected later in 2013, following the launch of JETREA® in the UK. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print